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Injection oflymphoid cells into healthy semiallogeneic hosts or immunocompro-
mised allogeneic recipients results in graft-vs.-host disease (GVHD)'. The course
ofGVHD can be acute orchronic, dependingon geneticand environmental factors.
Thusfar, studiesofthepathomechanismsinvolved in GVHDwere basedon transfer
ofwhole lymphoid cell populations, orTcells enriched for the CD4 or CD8 subset
into recipients differing from the donors at class I or class II MHC loci or both.
These studies have indicatedthatclass II MHC disparityand CD4 cells are required
fortheinductionofachronicGVHD(1-3). However, the requirements toelicit acute
GVHD have remained controversial. In the case ofunirradiated recipients, acute
GVHD occurs only in certain strain combinations of class I + class II disparity
after injection oflarge numbers (-108) oflymphoid cells (2, 3). Single MHC dis-
parities and T cell subsets reacting to therelevant disparatemolecules result in acute
lethal GVHD only in irradiated recipients (with or without bone marrow reconsti-
tution; references 4-8). The conclusion from these studies is that lethal GVHD is
mediated primarily by CD8 cells reacting to class I molecules ofthe recipient, and
to a smaller extent also by CD4 cells recognizing disparate class II molecules. The
effect of these two T cell subsets appears to be additive.
In an attempt to dissect the cellular requirements for GVHD, we have injected
class 1I-reactive cloned T cells into recipients expressing the stimulating class II
molecules. Theclones were foundtoinduce acutelethal graft-vs.-host reaction (GVHR)
without contribution ofthe hosts' immune system . The pathogenicity ofclones did
not correlate with their in vitro cytolytic activity. In this experimental system, in
vivo activation of the injected cloned cells appears to be the only requirement of
triggering thedisease, which ismanifested in severe vascularleakageas acauseofdeath.
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Materials and Methods
Mice.
￿
Mice of strains B10.A(2R), BIO.A(4R), BIO.AQR, B10.BR, B10.D2, B10.M, and
1310T(W) wereobtained from Olac Ltd. (Bicester, UK). BALB/c, BALB/c nu/nu, C57BL/6,
Address correspondence to Zoltan A. Nagy, Preclinical Research, Pharmaceutical Division, Sandoz
Pharma Ltd., CH-4002 Basel, Switzerland.
I Abbreviations used in this paper . GVHD, graft-vs.-host disease; GVHR, graft-vs.-host reaction; VLS,
vascular leak syndrome.
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CBA, and DBA/2 mice were purchased from Iffa Credo (L'Arbresle, France) ; and AKR mice
from Bomholtgard (Ry, Danemark) . C3H/HeN and C3H/HeJ mice were from Charles River
Wiga (Sulzfeld, FRG), and C3H nu/nu mice were from the Zentralinstitut fur Versuchstiere
(Hannover, FRG) . Mast cell-deficient (B6/C3H w"/w°)F, and congeneic nondeficient
(B6/C3H +/+)F, mice were kindly provided by Dr. W. Beamer (The Jackson Laboratory,
Bar Harbor, ME) . All mice were specific pathogen free, and were used when 2-3 mo old .
T Cell Clones .
￿
Clones were isolated from MLR combinations B10.A(4R) anti-B10.A(2R)
(4R anti-2R) and B10.T(6R) anti-B10.AQR (6R anti-AQR) . The former combination generates
I-Ek-specific response, and the latter induces I-A' as well as I-Ek-specific T cells . After four
cycles of weekly restimulation with irradiated stimulator cells and without exogenous IL-2,
the cells were cloned by a limiting dilution (0.3 cells/well), in the presence offresh stimulator
cells and human rIL-2 (10 ng/ml ; Sandoz Research Institute, Vienna, Austria) . The culture
medium was RPMI 1640 supplemented with 10% FCS, antibiotics, L-glutamine, and 2-ME.
Both4R and 6R clones were derived from two different cell lines, indicated either by numbers
or letters in the designation of clones. For maintaining without much expansion, the clones
(2 x 10 5 cells/ml) were stimulated once a month with irradiated stimulator spleen cells (2.5 x
106/ml) and rIL-2, and fed weekly with rIL-2 containing medium . To expand the clones to
large numbers (up to 5 x 10 8 ), 1 wk after restimulation with irradiated cells, the medium
was removed completely, and replaced by fresh IL-2 containing medium . 3-4 d later, in the
logphase ofgrowth, the cultures were split and diluted three to four times (cell concentration
readjusted to 2 x 105/ml) in IL-2 medium . The expansion was repeated every 3-4 d for 2
wk . The medium with nonadherent T cells was then removed completely, and the harvested
cells were used for experiments . Since the cells were semi-adherent at this phase of growth,
the ones adherent to the flasks after harvesting were sufficient to grow up again to saturating
cell numbers (_106/ml) for another 2 wk . After 1 mo of expansion, the cells stopped growing,
and required restimulation with fresh irradiated spleen cells and IL-2 . Large scale cultures
were performed in 500-ml flasks (Falcon Labware, Oxnard, CA) in 50-ml vol for restimula-
tion and 100 ml for expansion . The culture flasks were changed after 3-4 wk.
In Vitro Assays ofT Cell Clones.
￿
The specificity of clones was tested in a standard prolifera-
tion assay against different stimulator cells (2 x 104 cloned cells and 5 x 10 5 irradiated spleen
cells) cultured for 3 d with [3H]thymidine incorporation as a readout (9) . The clones were also
tested for cytolytic activity on LPS blast target cells as described previously (10) . Cell surface
expression of L3T4 and Lyt-2 molecules was tested by immunofluorescence using a
phycoerythrin-labeled anti-L3T4 and biotin-labeled anti-Lyt-2 mAb (Becton Dickinson &
Co., Mountain View, CA) . Surface staining was evaluated by a Facscan.
In Vivo Proliferation ofT Cell Clones.
￿
Cloned cells (10 7/mouse) were injected intravenously
in 0.5 ml PBS into syngeneic and stimulator strain recipients . After 60 h, 0.5 mCi methyl-
[3H]thymidine was injected intravenously into each mouse . Before injection, the alcohol con-
tent of thymidine was allowed to evaporate in a laminar flow hood for 4 h . After 18 h, the
animals were killed, and the lungs and liver removed . Each lung was washed three times
in PBS in 50-ml tubes by shaking at 4 0C for 2 d . After washing, the tubes were centrifuged,
and the lungs and the pelleted cells from the fluid phase were recovered and dissolved in
5 ml Soluene-100 (Packard Instrument Co., Inc ., Downers Grove, IL) at 37°C in glass .yials
(rocking for at least 24 h). The livers were minced, washed three times in 50 ml PBS by shaking
at 4'C for 1 h, and dissolved in 10 ml of Soluene-100 . 100-p1 aliquots of dissolved organs
were mixed with 3 ml scintillation fluid, and counted in the liquid scintillation counter.
Horning Assay.
￿
Cloned cells (107/ml) were labeled with 25 ACi/ml
51Cr for 1 h, washed
three times, and injected intravenously (10 7 cells/mouse) . 1 d later, mice were killed, dis-
sected, and the organs counted. The percentage counts recovered from each organ were related
to the sum of counts from the whole mouse taken as 100% . The latter value corresponded
to 70-80% of injected radioactivity (11) .
Exudation Assay.
￿
3 d after intravenous injection of 10 7 cloned T cells, 0.5 FACi of
'z5I
human albumin (Amersham, Buckinghamshire, UK) was injected intravenously. 2 h later,
the animals were exsanguinated, and radioactivity in individual organs was counted (12) .LEHMANN ET AL .
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Results
Characterization ofthe T Cell Clones Used.
￿
Clones derived fromMLRcombinations
4R anti-2R and6R anti-AQR were tested for proliferation against a panel of H-2-
different stimulator cells . The representative experiment in Table I demonstrates
that the reactivity of all 4R clones and of one 6R clone (6Re) requires the k allele
in the I-E region to be expressed by the stimulator cells. Accordingly, the response
ofthese clones canbe inhibited by anti-I-EmAb (datanot shown) . In contrast, clone
6R2 reacts to stimulator cells expressing the I-Ak molecule, and crossreacts to H-
2d and H-2r stimulator cells . The response to H-2d stimulator cells was inhibited
by anti-I-Ad mAb (data not shown) . These clones were also tested for cytolytic ac-
tivity (Fig . 1) . Four of the six clones exhibited cytotoxicity against LPS blast target
cells . The killer activity mapped concordantly with the proliferative response . All
six clones were Thy-1 +, L3T4+ , Lyt-2- , as detected by immunofluorescence, and
expressed message for IFN-'Y, IL-2, andTNF-0, but not forIL-4 (datanot shown) .
The latter characteristics classify the clones as Thl (13) .
MHC-specific Induction ofLethal GVHR by the T Cell Clones.
￿
Different numbers of
cloned cells were injected intravenouslyinto unirradiated recipients of different H-2
haplotypes . As shown in Table II, cloned cells caused 100% mortality within 5 d
in adose-dependent manner, provided that the recipients expressed the stimulatory
class II molecule. Moreover, clone 6R2 exhibited identical crossreactivities in vitro
and in vivo (Tables I and II) . In contrast, syngeneic recipients, and recipients whose
MHC molecules were not recognized by the clones, survived without any sign of
disease, even after injection of as many as 6 x 107 cells (data not shown) . All clones
were capable ofinducing lethalGVHD irrespective oftheir cytolytic activity in vitro,
rendering direct cytotoxicity as a mechanism of the disease unlikely.
2-3 d after injection of a lethal dose of cells, the animals started to exhibit the
typical symptoms of acute GVHD, such as ruffled fur, hunched posture, tachyp-
noea, apathia, hypothermia, and very rapid weight loss . Death of all animals oc-
curred on days 4 and 5. Sublethal cell doses of 3-5 x 106 cells also induced these
TABLE I
MHC Specificity of Proliferative Response by T Cell Clones
Significant responses are underlined .
Stimulator
cells from
Alleles at
H-2 loci Proliferative response by T cell clones
strain K A E D 4R9 4Rh 4R5 4Ra 6R3 6R2
cpm
B10.A(4R) k k b b 621 230 662 386 266 357.513 "
B10.A(2R) k k k b 58.438 99.338 104.076 96.080 89.482 273 .721
B10.T(6R) q q q d 1 .356 508 808 472 547 4 .000
B10.AQR q k k d 78.987 113.016 105 .578 71 .216 90.504 348 .068
1310.132 d d d d 591 271 667 428 422 464 .558
C57.131/6 6 6 b b 986 824 831 712 875 3 .264
1310.M f f f f 570 909 1 .334 414 669 234.8231488
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FIGURE 1 .
￿
Cytolytic activity ofT cell clones . Clones were tested for cytotoxicity on "Cr-labeled
LPS blast target cells from strains 2R (/) ; 4R (0) ; 6R (A) ; andAQR (A) .
symptoms, however, after day 5, the animals recovered and survived indefinitely .
The survivors failed to exhibit signs of chronicGVHD (e.g ., anti-DNA antibodies,
elevated Ig levels, lymphoid cell infiltrations) within an observation period of 6 mo.
Histological findings in the lethal syndrome were interstitial and alveolar oedema
of lungs, dystelektasia, hyalin membranesin alveoli, and intravascular fibrin deposits .
These findings are consistent with the diagnosis of shock . In the liver, focal mainly
subcapsular necrosis was seen, a finding also consistent with shock .
Homing andActivation ofTCell Clones In Viva
￿
Asshown in Fig . 2, all cloneshomed
preferentially to lungs andliver. After 24 h, 80-90% oftotal radioactivitywas recov-
ered from these two organs. The residual activity was distributed among spleen
(N5%), kidneys (ti3%), and skin (N3%). A slight preference in homing to the liver
wasseen in syngeneic mice and to thelungs in stimulator strain mice. We then inves-
tigated whether the cloned cells became activated at the sites of homing by using
an in vivo [3H]thymidine incorporation assay. The data in Fig . 3 demonstrate adra-
matically increased thymidine incorporation in the lungsofstimulator strain recipients,
as compared with syngeneic animals . A similar although less clear-cut difference
wasmeasured also in the liver . As shown in Table III, despite irradiation of thehosts
with 2,000 rad before injection ofthe cloned cells, 56% of the thymidine incorpora-
tion was still detectable . Thus, the majority of proliferative response appears to be
contributed by the injected cells, although a host component is also present . Inhibi-
tion ofDNA synthesis of the clone with mitomycin C before injection reduced the
in vivo proliferation by 95%. Thus, thehost component ofthymidine incorporation
05R
30 30
201
10 0
01~ 0
-101 -11 .5 x 10 7 cells are required for 100% mortality .
Not determined .
LEHMANN ET AL .
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TABLE II
MHC Specificity and Cell Dose Dependence of Lethal GVHD Induced by T Cell Clones
also seems to depend on activation of the injected cells. When the DNA synthesis
was inhibited in both cloned cells and host, no increase in thymidine incorporation
was observed . These results strongly suggest that the injected cells become activated
and proliferate in stimulator strain hosts.
Vascular Leakage Induced by TCell Clones in Stimulator Strain Recipients.
￿
The patho-
logical findings raised the possibility that T cell activation might be accompanied
by vascular leakage . This was investigated by extravasation of Iz'I albumin 3 d after
injection of cloned cells. The representative experiments in Fig . 4 demonstrate a
highly increased vascular leakage in the lungs and, to some extent, also in the liver
ofstimulator strain mice, ascompared with syngeneic animals. Thevascular leakage
in syngeneic mice did not significantly differ from that in mice without injected cells.
Acute Lethal GVHR Does not Require Host-derived Mechanisms .
￿
Shock and vascular
FIGURE 2 .
￿
Homing of cloned T cells in syn-
geneic and allogeneic recipients . 5'Cr-labeled
clonedT cells (107/recipient) were injected intra-
venously. Percent activity was calculated as de-
scribed in Materials and Methods . Each column
represents the mean (and SD) for three mice.
Recipient
strain K
Alleles at
H -2 loci
A E D
No . of cloned
cells injected
per animal 4R9
Mortality on
injection
4Rh 4R5
day 5 after
of clone
4Ra 6Re 6R2
B10.A(4R) k k b b 10 7 . 0/5 0/4 0/3 0/3 0/3 5/5
B10.A(2R) k k k b 10 7 5/5 5/5 4/4 4/7' 3/3 3/3
7 .5 x 10 6 4/5 -1 - - - -
5 x 10 6 2/8 2/5 - - - -
2 .5 x 106 0/5 0/4 - - - -
B10.T(6R) q q q d 10 7 0/3 0/3 0/3 0/3 0/3 0/4
B10.AQR q k k d 10 1 3/3 3/3 4/4 3/5' 10/10 6/6
7 .5 x 10 6 - - - - 9/10 5/5
5 x 106 - - - - 4/8 2/5
2 .5 x 10 6 - - - - 0/4 0/6
1310 .D2 d d d d 10 7 - - - - 0/3 3/3
C57 131/6 b b b b 10 1 - - - - 0/3 0/3
BlO.M f f f f 10 7 - - - - 0/3 6/61490
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leakage can result from several different inflammatory mechanisms . For example,
TNF has been implicated in shock (14, 15), while mast cell degranulation (16, 17)
and activated complement factors, in particularC5a (18), are known to increase vas-
cular permeability . As shown in Table IV, mouse strains expressing the stimulatory
class II molecule, and carrying genetic defects causing deficiency of C5, TNFcl,
and mast cells, respectively, are as sensitive to the lethal disease as the nondeficient
wild-type strains . Moreover, athymic nude mice were also sensitive to the disease
and develop vascular leakage (Table V), indicating that the host's ownT cell system
plays little ifany role in thepathogenesis ofTcell clone-induced acute lethal GVHR .
Inactivation of the complement system by cobravenom factor also failed to prevent
lethal GVHR (Table VI). We also investigated whether or not antiinflammatory
drugs with defined sites of action would interfere with the disease . The results are
summarized in Table VII . Dexamethasone, an inhibitor of protease release from
phagocytic cells (19), prostaglandin inhibitors indomethacin and acetylsalicylic acid,
as well as Wortmannin that blocks the release of oxygen radicals from activated gran-
ulocytes and macrophages (20), were all ineffective in preventing or ameliorating
TABLE III
In Vivo 13HJTdR Incorporation Reflects Activation of the
Injected T Cell Clone
FIGURE 3 .
￿
In vivo [3H]TdR incorporation
induced byT cell clones in syngeneic and al-
logeneic recipients. 3 d after injection ofcloned
cells, recipient mice were given 0.5 mCi
[3H]TdR, and the radioactivity in lungs and
liver was determined as described in Materials
and Methods . Each column represents the
mean (and SD) for three mice .
' 107 cells/recipient .
1 Mean + SD for three mice/group .
5 Mitomycin C (50 hg/ml) for treating 10 7/ml cells .
Recipient
Strain Treatment
rad
Clone
Designation
injected
Treatment
[3H]TdR
incorporation
in lungs
cpm
B10.A(4R) - - - 4,499 ± 7701
B10.A(4R) - 4R9 - 4,610 t 1,131
B10.A(2R) - - - 1,753 f 248
B10.A(2R) 2,000 - - 838 t 153
B10,A(2R) - 4R9 - 76,480 t 3,339
B10.A(21t) 2,000 4R9 - 42,657 ± 1,375
B10.A(2R) - 4R9 Mitoycin C4 3,618 t 932
B10.A(2R) 2,000 4R9 Mitoycin C 1,046 t 10LEHMANN ET AL .
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the disease . Thus, secondary inflammatory reactions do not appear to be crucial
for thepathogenesis oflethal GVHR . Of the drugs tested, only cyclosporin prevented
the disease, probably by inhibiting activation ofthe injected cells themselves . Irradi-
ated mice also developed thedisease (datanot shown) . Collectively, the results argue
against the involvement ofhost-derived mechanisms, and indicate by exclusion that
the injected cloned cells directly induce vascular leakage and death .
Discussion
In this study, we have demonstrated that class II-specific Thl cell clones can in-
duce acute lethal GVHR in an antigen-specific manner upon injection into unir-
TABLE IV
Failure ofNon-H-2 Background to Influence Lethal GVHD
1 .2 x 107 of cloned cells were required for 100% mortality .
1 1 .5 x 10 7 cells were injected .
S 2 x 107 cells were required for 100% mortality .
FIGURE 4 . Extravasation of
1251 albumin induced byT cell
clones . 3 d after injection of
cloned cells 1211 human al-
bumin was injected and the ex-
udation assay performedas de-
scribed (14) . Each column
represents the mean (and SD)
for four mice .
Designation
Recipient strain
H-2
haplotype
Genetic
defect
Mortality by day 5
after injection of
10 7 cells of clone
4R9 6R2
B10.BR k - 2/2 3/3
AKR k C5 5/6 3/3
CBA k - 3/3 3/3
C3H/HeN k TNF-a 3/3 3/3
C3H/HeJ k - 5/5 3/3
C3H nu/nu k Athymic 4/6' 3/3
(B6xC3H +/+)Fl b/k - 3/3 2/31
(B6xC3H w"/w°)Fl b/k Mast cells 3/3 3/31
B10.D2 d - - 3/3
DBA/2 d C5 - 3/3
BALB/c d - - 3/3
BALB/c nu/nu d Athymic - 4/4S1492
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TABLE V
T Cell Clone Induced Extravasation of 1251 Albumin in Nude Mice
* Mean f SD for four mice/group.
radiated recipients. This disease exhibits similarities to, as well as differences from,
theclassical acuteGVHD observed afterinjection ofpolyclonallymphoid cell popu-
lations into semiallogeneic or irradiated hosts. The similarities include the nature
ofimmunologic trigger, the clinical symptoms, and therapid, therapy-resistant fatal
course. However, the clone-induced disease has a more rapid course, which can be
explained by the large number of injected antigen-primed cells, as compared with
the low frequency ofunprimed precursor T cells in polyclonal cell populations. An-
other difference is that the clone-induced disease is restricted to the lungs and liver
due to preferential homing to these organs, whereas the classical disease involves
the bone marrow, lymphatic system, liver, gastrointestinal tract, and the skin (21).
It should be pointed out that preferential homing to lungs and liver is not only the
property ofin vitro derived clones (22, 23), but appears also to be the physiological
consequence ofin vivo Tcell activation (24, 25), although inthe latter case, localiza-
tion ofactivated T cells to other tissues, such as the spleen and intestines, has also
been reported (26). It is, therefore, unlikely that alteredhomingis the sole explana-
tion for the differences between GVHD induced by Thl clones and bulk lymphoid
cells, respectively. Presumably, other Tcell subclassesnot represented by ourclones,
such as Th2 and CD8+ cells, are responsible for additional features of the disease.
In agreement withprevious studies(27, 28), antigen-specific activation ofthecloned
cells in vivo is a prerequisite for disease induction. This is reflected by increased
TABLE VI
Inactivation of the Complement System Fails to Prevent
Lethal GVHD by T Cell Clones
Clone injected
* Cobra Venom Factor from Naja naja kaouthia, intraperitoneally.
2 20 U 1 d before injection of clone, 10 U/d on the following 2 d .
9 10 U/d starting 4 h before injection of the clone.
Recipient Clone injected Mortality
strain CVF* Designation Cell no . by day 5
U
B10.A(4R) 402 None - 0/3
B10.A(4R) 402 6R2 101 4/4
B10.A(4R) - 6R2 101 3/3
Bl0.BR 309 None - 0/2
BlO.BR 309 We 101 5/5
B10.BR - 6Re 101 3/3
Recipient Designation Specificity No. Acitivity in lungs
BALB/c nu/nu - - 50,997 f 20,212*
BALB/c nu/nu 6Re I-El 2 x 101 58,349 ± 27,542
BALB/c nu/nu 6R2 I-A' 2 x 101 129,015 ± 17,893LEHMANN ET AL.
￿
1493
TABLE VII
Effect of Anti-inflammatory Drugs on Lethal GVHD Induced by T Cell Clones
' Dissolved in 0.5% tragecanth.
thymidine incorporation in theinflictedorgans. Thethymidineis taken up to alarge
extent by the injected cells themselves, indicating proliferation of these cells in the
host. However, the in vivo proliferative response possesses a distinct host compo-
nent, whose nature is unknown. This component is clearlydependenton the recog-
nition of the stimulating antigen in the host by the injected cloned cells. Possible
candidates for proliferating host cells -are, first, -host lymphoid cells attracted and
activated by lymphokines secreted by the injected cells; second, nonlymphoid cells,
e.g., fibroblasts responding to clone-derived lymphokines; and third, host cells
mounting an antiidiotypic response against the clone. The latter possibility is ren-
Recipient
strain Drug Dose Route
Clone
injected
Mortality
by day 5
mglkgld
C3H/HeJ Dexamethason 50 s.c. - 0/3
C3H/HeJ Dexamethason 50 s.c. 6112, 8 x 106 4/4
C3H/HeJ Dexamethason 10 s.c. 6R2, 8 x 106 3/4
C3H/HeJ - - - 6R2, 8 x 106 3/3
B10.A(2R) Dexamethason 50 s.c. 4119, 8 x 106 4/4
B10.A(2R) Dexamethason 10 s.c. 4R9, 8 x 106 3/3
B10.A(2R) - - - 4R9, 8 x 106 3/3
C3H/HeJ Indomethacin 10 P.O. - 0/3
C3H/HeJ Indomethacin 10 P.O. 6R2, 8 x 106 4/5
C3H/HeJ Indomethacin 5 P.O. 6R2, 8 x 106 3/3
C3H/HeJ - - - 6R2, 8 x 106 3/3
C3H/HeJ Indomethacin 10 P.O. 4R9, 6 x 106 3/4
C3H/HeJ Indomethacin 5 P.O. 4R9, 6 x 106 3/4
C3H/HeJ - - - 4R9, 6 x 106 3/3
C3H/HeJ ASA 500 p.o . - 0/3
C3H/HeJ ASA 500 p.o . 4R9, 107 4/4
C3H/HeJ ASA 150 p. o. 4R9, 107 3/3
C3H/HeJ - - - 4R9, 107 3/3
C3H/HeJ Wortmannin" 3 p.o. - 0/4
C3H/Hej Wortmannin' 3 p.o. 4R9, 107 4/4
C3H/HeJ Wortmannin' 1 P.O. 4R9, 107 4/4
C3H/HeJ - - - 4R9, 107 3/3
C3H/HeJ Wortmannin` 3 P.O. 6R2, 107 4/4
C3H/HeJ Wortmannin' 3 P.O. 6R2, 107 4/4
C3H/HeJ Cyclosporin 100 P.O. - 0/4
C3H/HeJ Cyclosporin 100 P.O. 6R2, 107 1/6
C3H/HeJ Cyclosporin 50 P.O. 6R2, 107 0/8
C3H/HeJ Cyclosporin 25 P.O. 6R2, 107 0/4
C3H/HeJ - - P.O. 6112, 107 3/3
B10.A(2R) Cyclosporin 100 P.O. 4119, 8 x 106 0/3
B10.A(2R) Cyclosporin 50 p.o. 4119, 8 x 106 0/3
B10.A(2R) - - p.o. 4119, 8 x 106 3/31494
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dered unlikely by the observations that mitomycin-treated cellsfail to induce significant
thymidine incorporation, and that this reaction is very pronounced already on day 3.
The in vivo activation of T cell clones is followed by a vascular leak syndrome
(VLS) leading to death of the recipients. This syndrome has been previously de-
scribed as a severe side effect of IL-2 therapy (29, 30). The latter type of VLS ap-
peared to result from the activation of host lymphoid cells, particularly NK cells,
by IL-2 (12, 31). Our study is the first to demonstrate that Th cell clones can induce
VLS and lethal disease without the participation of several inflammatory mecha-
nisms of the host, such as mast cell degranulation, generation of vasoactive or ana-
phylatoxic complement components, and release of proteases and oxygen radicals.
By exclusion, therefore, the injected Th cells themselves are likely to induce vascular
leakage directly. These results raise the possibility that the edema often accompanying
T cell-dependent tissue reactions, such as delayed-type hypersensitivity, may also
be directly triggered by T cells, and is not the consequence of secondary inflamma-
tory mechanisms, as assumed previously (16). Thus, the capability of Th cells to
induce vascular leakage can be considered as an effector mechanism, which facili-
tates the accumulation ofinflammatory cells, and serum proteins at the site ofpathogen
invasion.
Summary
T cell clones isolated from class II MHC-disparate MLR combinations, and specific
for I-A' and I-E' molecules, respectively, are shown to induce acute lethal graft-vs.-
host disease in unirradiated recipients. Cytolytic and noncytolytic clones are equally
efficient in this respect. The lethal disease is dependent on recognition ofthe stimula-
tory class II molecules in the host. The clones home to lungs and liver, and become
activated in these organs as demonstrated by an in vivo thymidine incorporation
assay. After activation, a severe vascular leak syndrome develops causing death of
the recipients within 5 d after the injection of 5 x 106 to 10' cloned cells. The dis-
ease develops without the participation ofsecondary host-derived inflammatory mech-
anisms, such as mast cell degranulation, complement activation, and the release of
prostaglandins, oxygen radicals, or proteolytic enzymes. The results raise the possi-
bility that Th cells can directly influence vascular permeability, and control, thereby,
the acute inflammatory reaction of blood vessels.
Receivedfor publication 14 August 1989 and in revisedform 28 November 1989.
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